

Innovotech Inc. Reports 2018 First Quarter Financial Results

Edmonton, May 17, 2019. Innovotech (the “Company”), a leader in contract research in connection with the susceptibility of medical devices to microbial biofilm formations has released its financial and operating results for the first quarter ended March 31, 2019.

For the three months ended March 31, 2019, the Company recorded a net loss of \$14,518 on revenues of \$222,020 compared with a net loss of \$42,398 on revenues of \$215,796 in the first quarter of the prior year. The reduced loss indicates that steps taken to reduce general and administrative costs and R&D expenses are gaining traction, and that ought to continue into the second quarter. On revenues, the Company anticipates growth associated with the Company’s recent ISO 17025 accreditation. Achieving that accreditation was the highlight of the first quarter.

FINANCIAL RESULTS

	Q1 2019	Q1 2018
	In Canadian \$	
Contract research fees	149,448	162,119
Product sales	72,573	53,677
Gross revenue	222,021	215,796
Cost of goods sold	69,090	64,412
Gross profit	152,931	151,384
General and administrative	161,471	210,280
Sales and marketing	-	85
Research & development	4,477	17,546
Interest expense	1,501	-
Net profit (loss)	(14,518)	(42,398)
Per share, basic and diluted	(0.00)	(0.00)

The Company’s silver periodate compound, InnovoSIL™-1 continues under evaluation by third parties for applications in wound care and medical device coatings.

On behalf of the Board of Directors,

Alan C Savage
Director & CFO

This document may contain forward-looking statements that are predictive in nature and subject to risks and uncertainties that cannot be predicted or quantified. Actual results may differ materially from past results and those expressed or implied by any forward-looking statements. Factors that could cause or contribute to such risks or uncertainties include, but are not limited to: the regulatory environment; changes in the value of the Canadian dollar; the Company’s reliance on a small number of customers; fluctuations in operating results; government policies or actions; progress and cost of clinical trials; reliance on key strategic relationships; uncertainty related to intellectual property protection and potential costs associated with its defense; the Company’s exposure to lawsuits and other matters beyond the control of management. Should known or unknown risks or uncertainties materialize, or should management’s assumptions prove inaccurate, actual results could vary materially from those anticipated. The Company undertakes no obligation to publicly make or update any forward-looking statements, except as required by applicable law.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.